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Abstract
Hbs1 has been established as a central component of the cell’s translational quality control
pathways in both yeast and prokaryotic models; however, the functional characteristics of
its human ortholog (Hbs1L) have not been well-defined. We recently reported a novel
human phenotype resulting from a mutation in the critical coding region of the HBS1L gene
characterized by facial dysmorphism, severe growth restriction, axial hypotonia, global
developmental delay and retinal pigmentary deposits. Here we further characterize down-
stream effects of the human HBS1L mutation. HBS1L has three transcripts in humans, and
RT-PCR demonstrated reduced mRNA levels corresponding with transcripts V1 and V2
whereas V3 expression was unchanged. Western blot analyses revealed Hbs1L protein
was absent in the patient cells. Additionally, polysome profiling revealed an abnormal aggre-
gation of 80S monosomes in patient cells under baseline conditions. RNA and ribosomal
sequencing demonstrated an increased translation efficiency of ribosomal RNA in Hbs1L-
deficient fibroblasts, suggesting that there may be a compensatory increase in ribosome
translation to accommodate the increased 80S monosome levels. This enhanced transla-
tion was accompanied by upregulation of mTOR and 4-EBP protein expression, suggesting
an mTOR-dependent phenomenon. Furthermore, lack of Hbs1L caused depletion of Pelota
protein in both patient cells and mouse tissues, while PELO mRNA levels were unaffected.
Inhibition of proteasomal function partially restored Pelota expression in human Hbs1L-
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deficient cells. We also describe a mouse model harboring a knockdown mutation in the
murine Hbs1l gene that shared several of the phenotypic elements observed in the Hbs1L-
deficient human including facial dysmorphism, growth restriction and retinal deposits. The
Hbs1lKO mice similarly demonstrate diminished Pelota levels that were rescued by protea-
some inhibition.
Author summary
We have identified a patient with biallelic mutations in HBS1L affecting Hbs1LV1 and V2
transcripts leading to a loss of Hbs1L implicated in ribosomal recycling. In contrast to
yeast studies, loss of Hbs1LV1/V2 in human cells did not appear to impact the transla-
tional quality control mechanisms of non-stop and no-go decay. However, patient cells
demonstrated accumulation of free 80S ribosomes based on polysome profiling. In addi-
tion, Hbs1LV1/V2 deficient cells demonstrated an increase in translation efficiency of
ribosomal mRNA based on RiboSeq data, which may suggest an attempt to compensate
for defective mobilization of free 80S ribosomes. The patient samples demonstrated
increased 4EBP1 and mTOR expression and phosphorylation compared to controls, sug-
gesting an mTOR-dependent ribosomal RNA regulation is involved in the response to
Hbs1LV1/V2 deficiency. Loss of Hbs1L in both human and mouse fibroblasts lead to
diminished Pelota levels, and this phenomenon could be partially rescued by proteasome
inhibition. In all, these data support a role for Hbs1LV1/V2 as a Pelota binding partner
with a specific function in utilization of free ribosomes.
Introduction
Hbs1L belongs to a specialized family of translational GTPases (trGTPases), members of
which are structurally homologous but functionally distinct [1]. Each trGTPase binds to a spe-
cific “decoding” protein and transports it to the ribosomal A site, where it recognizes a unique
mRNA code. In mammals, eEF1A transports aminoacyl (aa)-tRNAs to sense codons, eRF3
transports eRF1 to termination codons, and Hbs1L transports Pelota to stalled ribosomes
with either an empty A site or an mRNA-occupied A site without sequence preference [2, 3].
Engagement of each decoding protein with the ribosome initiates a distinct anabolic event: aa-
tRNAs lengthen the nascent chain, eRF1 terminates translation, and Pelota triggers mRNA
surveillance pathways.
mRNA surveillance is a critical component of translational quality control (tQC) in all cells.
There are three mRNA surveillance pathways that have been well-defined in eukaryotes, each
of which is responsible for the selective degradation of a specific class of aberrant mRNA. Non-
sense-mediated decay (NMD) targets sequences containing a premature termination codon
[4], non-stop decay (NSD) degrades mRNAs lacking any termination codon [5, 6], and no-go
decay (NGD) targets mRNAs containing cis-acting features that cause translational arrest [7].
Pelota:Hbs1L has been implicated in NGD and NSD in plants and eukaryotes [7–11]. Our
understanding of its role in these processes is largely predicated on studies in Saccharomyces
cerevisiae of the orthologous protein complex, Dom34:Hbs1. Yeast Hbs1 (Hsp70 subfamily B
suppressor 1) was originally identified for its ability to rescue stalled ribosomes by suppressing
Hsp70 (heat shock protein 70) activity [12]. Subsequent studies structurally associated Hbs1
with eRF3 and eEF1A [13], and recognition of Dom34 as an Hbs1-interacting protein
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functionally linked the complex to translation [14]. Recent biochemical studies have shown
that Dom34:Hbs1 promotes the dissociation of the stalled ribosome into subunits [8, 15, 16]
during aberrant translation. Subunit dissociation is a critical component of canonical ribo-
somal recycling, a process to reutilize ribosomes from a terminated or aberrant round of
translation.
Hbs1 and Dom34 have additionally been implicated in ribosomal recycling mechanisms
outside of canonical tQC pathways. For example, the Dom34:Hbs1 complex has been sug-
gested to play a role in ribosomal recycling of inactive 80S monosomes in yeast cells recovering
from stress [17]. Under stress conditions, free ribosomal subunits associate to form large pools
of inactive 80S monosomes stabilized by the ‘clamping’ Stm1 factor [17–22]. This effectively
limits or inhibits translation, allowing the cell to reserve metabolic resources and protect ribo-
somal subunits from damage and degradation. Dom34:Hbs1 has been shown to work in con-
junction with Rli1 (ABCE1 in mammals) to dissociate inactive ribosomes following stress
relief, thus playing a critical role in translation re-initiation during stress recovery [17]. Inter-
estingly, 80S monosome accumulation has been observed in Hbs1- and Dom34- deficient
yeast cells even in non-stressed conditions, suggesting that under normal conditions there
may be inactive ribosomes that require Dom34:Hbs1-mediated dissociation prior to starting
translation [17].
We have previously described an Hbs1L-deficient patient with a phenotype that included
severe intrauterine growth restriction, microcephaly, axial hypotonia, lax joints, global devel-
opmental delay, fused C2-C3 vertebrae, scoliosis, submucous cleft palate and retinal pigmen-
tary deposits [23]. We have now interrogated Hbs1L-deficient mice that demonstrated a
similar phenotype. Our data demonstrate that one of the important functions of Hbs1L in
mammals is to stabilize Pelota protein, and proteasomal inhibition can increase Pelota levels
in the Hbs1L-deficient cells. Furthermore, Hbs1L:Pelota appear to be important for utilization
of free 80S ribosomes, and in the absence of Hbs1L, there is an increase in ribosomal RNA
translation efficiency (TE) which may act to compensate for the impaired ability to utilize 80S
monosomes.
Results
Hbs1L deficiency leads to a unique phenotype featuring growth restriction,
facial dysmorphism, and developmental delay
The HBS1L:MYB locus has been linked to a number of hematological traits including fetal
hemoglobin levels, red and white blood cell counts, and platelet counts by genome-wide asso-
ciation studies (GWAS) [24–27], and we have previously described a female child with no
apparent hematological abnormalities carrying compound heterozygous mutations resulting
in Hbs1L deficiency [23]. The child had multiple congenital anomalies (MCA) of unknown
molecular basis. These included sparse hair and eyebrows, deep-set eyes with blue sclerae,
bifid uvula with a submucous cleft palate, velopharyngeal insufficiency, C2-C3 vertebral
fusion, scoliosis, vesicoureteral reflux with a bladder diverticulum, significant hypotonia, and
global developmental delay [23]. To delineate the phenotype further, the patient was born at
37 weeks gestation with severe symmetric intrauterine growth restriction, weighing only 1530
grams at birth (<1st percentile, z-score -3.72), head circumference of 29.5 cm (<1st percentile,
z-score -2.59) and length of 41 cm (<1st percentile, z-score -2.84). Growth restriction persisted
throughout childhood, and at four years old she remained at the 3rd percentile for height, the
1st percentile for weight, and the 0.5th percentile for head circumference (Fig 1A).
In addition to the facial findings described previously, the patient had low posterior hair-
line, low-set ears, midface hypoplasia, a thin nose with a small mouth and small teeth, and
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small medial clefts on the lower third of each eyelid. Further issues include dysphagia with
aspiration, chronic sinus disease and left-sided conductive hearing impairment needing tym-
panostomy tube. The patient also displayed thirteen pairs of ribs. She had no history of anemia,
abnormal bleeding, or increased infectious susceptibility, and routine complete blood counts
revealed normal hematocrit indices and red blood cell, white blood cell, and platelet counts
over time. The patient’s mother, father, and younger brother had no medical problems and
extensive family history revealed no other family members with similar constellations of
symptoms.
The patient’s muscle bulk was greatly diminished throughout the body; axial muscles more
affected than appendicular. She had delayed motor milestones as she began to sit unsupported
at twelve months and achieved independent ambulation at six years. Her psychological testing
at four years demonstrated significant delays in language development and fine and gross
motor development, although nonverbal reasoning skills were average. The patient had some
astigmatism and decreased visual acuity (20/100 OS and 20/80 OD), and retinal examination
revealed diffuse pigmented deposits (Fig 1B).
Magnetic resonance imaging (MRI) at 30 months showed prominence of the ventricles
and sulci with rare, scattered non-specific foci of T2 prolongation in the cerebral white matter
Fig 1. Clinical findings in patient with Hbs1L-V1 and V2 deficiency. (A) Growth restriction was sustained from
birth through childhood. References shown are WHO standards. (B) Retinal imaging showing bilateral
hyperpigmented deposits. (C) MRI showing prominence of the ventricles and sulci without parenchymal signal
abnormalities.
https://doi.org/10.1371/journal.pgen.1007917.g001
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(Fig 1C). Her electromyography was normal. Renal ultrasound revealed asymmetry (right
larger than left) with a duplex right kidney.
Compound heterozygous HBS1L mutations cause deficiency of Hbs1L-V1
and V2 but not V3
The patient had a normal 46, XX karyotype and a normal chromosomal microarray. Whole-
exome sequencing was subsequently performed on the trio as reported previously revealing a
null splice donor mutation (hg19; chr6:135287466, c.2043+1G>T) inherited from the father
and a nonsense mutation (hg19; chr6:135290431, NM_006620: c.1843C>T:p.R615X) inherited
from the mother in HBS1L [3, 23]. Western blot analysis revealed no detectable expression of
Hbs1L-V1 and V2 proteins in patient fibroblasts and LCLs (Fig 2A–2C), although a band cor-
responding to the expected location of Hbs1L-V3 [2] was present and was similar to controls.
RT-PCR similarly demonstrated decreased HBS1L transcript levels when probing for exons
2–4 (V1, V2 and V3), marked reduction in exons 15–17 (only present in V1 and V2), and no
change in transcript levels for exon 5 of the V3. This reflects depletion of the HBS1L-V1 and
V2 variants, and essentially no change in HBS1L-V3 transcript levels compared to controls
(Fig 2D).
Pelota expression decreases with Hbs1L deficiency and increases with
proteasome inhibition
As Pelota is a known interacting partner of Hbs1L, we evaluated its abundance using Western
blot. Pelota levels were markedly reduced in patient fibroblasts relative to controls (Fig 2B–
2C). In order to determine whether this change occurred on the messenger RNA (mRNA)
level, a reverse transcription polymerase chain reaction (RT-PCR) was used to compare the
abundance of PELO transcripts in patient and control fibroblasts. PELO levels were compara-
ble between them (Fig 2D), indicating that the absence of Hbs1L did not alter PELO transcript
levels. Western blotting experiments were then repeated in the presence of a 20S proteasome
inhibitor to evaluate Pelota stability in absence of Hbs1L. Proteasome inhibition was found to
increase abundance of Pelota, drastically increasing at the initial 0.2 μg/mL dose, but then pro-
gressively decreased with higher doses of 0.5 and 1.0 μg/mL suggestive of toxic effects at higher
doses. This pattern was noted in both patient and control cells (Fig 2E).
Hbs1L-deficient patient cells have higher baseline levels of 80S ribosomes
Hbs1L has been implicated in the recycling of inactive ribosomes after periods of cell stress to
promote translational re-initiation [17]. In order to investigate the effect of Hbs1L deficiency
on this process, a glucose starvation assay was performed and polysome profiles were assessed
on and fibroblasts from patient and control cell lines. Interestingly, patient fibroblasts dis-
played an increased 80S monosome peak relative to controls under baseline conditions. When
the fibroblast samples subsequently underwent starvation, the 80S peak rose in control cells to
match the patient baseline level, whereas the patient cells showed no significant changes (Fig
3A). The total ribosome content and the ratio of monosomes to polysomes were increased in
the patient fibroblasts (Fig 3B).
Hbs1L-deficient cells demonstrate normal ribosomal RNAs
Ribosomal RNAs (rRNAs) are critical for the maturation and assembly of ribosomal subunits.
In order to investigate whether Hbs1L exerts influence over ribosomal processing, we analyzed
the levels of several 18S rRNA intermediates (45S, 43S, 41S, 30S, 21S, 18S-E) and 28S rRNA
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intermediates (45S, 43S, 41S, 32S, 12S) in the patient-derived Hbs1L-deficient LCLs and three
unrelated control cell lines by Northern blot analysis using probes complementary to the ITS1
and ITS2 sequences, respectively (Fig 4A). Bands for each of these intermediate species were
quantified and calculated as product to precursor ratios. In patient cells, 18S precursor pre-
Fig 2. Biallelic mutations in human HBS1L lead to Hbs1L deficiency and decreased Pelota protein. (A) Schematic
of Hbs1L isoforms V1, V2, V3 indicating exon changes. (B) Western blots probing for Hbs1L, Pelota, ABCE1, and
GAPDH protein expression in EBV-transformed lymphocytic cell lines (LCL) and dermal fibroblasts derived from
patient and controls. Bands corresponding to Hbs1L isoforms 1/2 and 3 are indicated. (C) Density read-out from
Western blot of fibroblasts depicted in B. (D) Relative expression (in fold change versus control) of HBS1L transcripts
as determined by RT-PCR using primers to HBS1L-V1, V2, and V3 (exons 2–4), primers to HBS1L-V1 and V2 only
(exons 15–17), and primers specific to exon 5 of HBS1L-V3, as well as primers to PELO exons 2–3 (PELO 1) and exon
2 (PELO 2). (E) Dose response curve to proteasome inhibition with Bortezomib showing Pelota expression by Western
blot for increasing concentrations of Bortezomib in control and Hbs1L-deficient (0128–01) dermal fibroblasts. Each
experiment represents a minimum of two technical replicates with highly similar results.
https://doi.org/10.1371/journal.pgen.1007917.g002
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rRNA ratios 41S/45S, 30S/41S, 21S/30S, and 18S-E/21S, as well as 28S precursor pre-rRNA
ratios 32S/41S and 12S/32S, were similar to controls (Fig 4B). 18S/28S rRNA ratios were also
in the same range for patient and control cells, as demonstrated by Western blot analysis
(Fig 4A, lower panel).
In addition to patient’s cells, small interfering RNA (siRNA) experiments were used to
investigate the role of Hbs1L in rRNA processing. HeLa cells were treated with one of two dif-
ferent anti-HBS1L siRNAs: HBS1L-1 targeted HBS1L-V1, V2, and V3 transcripts, whereas the
action of HBS1L-2 was restricted to HBS1L-V1 and V2, as attested by Western blot (S1 Fig).
Fig 3. Hbs1L-deficient fibroblasts have elevated 80S ribosomal monosome levels. (A) Polysome profiles of Hbs1L-
deficient (bottom panels) and control fibroblasts under fed (+15% FBS) and starved (20–24 hours without FBS)
conditions. The polysome profile is representative of 3 independent technical replicates with highly similar results. (B)
Ratios of monosomes and polysomes for control and patient fibroblasts. p-value determined by paired t-test.
https://doi.org/10.1371/journal.pgen.1007917.g003
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HeLa cells treated with siRNA HBS1L-1 showed some reduction of the 30S/41S ratio compared
to controls and a concomitant increase of 21S/30S and 18S-E/21S ratios, indicating a slight
accumulation of late precursors to the 18S rRNA (S1 Fig). In contrast, cells treated with siRNA
HBS1L-2 showed no significant changes in the expression of any pre-rRNA species relative to
controls.
RNA expression analysis suggestive of involvement of skeletal, urogenital,
and eye development pathways
Patient-derived and control epidermal fibroblasts were used to generate an mRNA library for
mRNA-Seq. Principle component analysis (PCA) demonstrated clustering of patient and
control samples between technical replicates (S2 Fig). Furthermore, gene coverage was simi-
lar between two control fibroblast lines and between independent experimental replicates for
both patients and controls. Gene expression analysis for biological processes showed that
1601 of 3730 gene sets were upregulated in patient fibroblasts, with 585 gene sets significant
using FDR <25% and 275 gene sets being significantly enriched at p <0.01. 713 gene sets
were significant downregulated at FDR <25% and 300 at p<0.01 (S1 Table). Gene ontology
assessment demonstrated major changes in biological process pathway expression for many
skeletal and renal pathways, as well as sensory pathways, specifically relating to the eye (Fig
5A). In addition, several gene sets relating to organ development were different between
Fig 4. Ribosomal RNA profiles are similar in Hbs1L-deficient and control LCLs. (A) Northern blot analysis of total RNAs
extracted from control or Hbs1L-deficient LCLs. Pre-rRNA species were evidenced with 5’ITS1 and ITS2 probes, revealing
precursors to the 18S rRNA (component of the small ribosomal subunit) and the 5.8S and 28S rRNAs (components of the large
ribosomal subunit), respectively. (B) Pre-rRNAs were quantified and log2 ratios of product to precursor pre-rRNA species, or 18S to
28S rRNAs, were calculated and normalized to the mean value obtained for 3 healthy controls (controls 1–3). The data were obtained
from three independent experiments (± S.E.M.).
https://doi.org/10.1371/journal.pgen.1007917.g004
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patients and controls. Furthermore, the axon development pathway was significantly altered
in the patients, which is of interest given the patient’s diffuse weakness without evidence of
myopathy.
Cellular component analysis showed that 316 of 488 gene sets were upregulated in patient
fibroblasts, with 163 gene sets significant using FDR<25% and 82 gene sets being significantly
enriched at p<0.01 (S2 Table). 71 gene sets were significant downregulated at FDR<25% and
Fig 5. Differential pathway expression by RNASeq. (A) Differences in expression of gene ontology pathways by
biological process. Skeletal, eye, and renal pathways were overrepresented and are indicated with cartoons. (B)
RNASeq gene ontology map by biological process outputs from REVIGO ontology software.
https://doi.org/10.1371/journal.pgen.1007917.g005
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35 at p<0.01. By gene ontology assessment, the most differentially expressed groups were posi-
tive regulation of biological process, system development, and extracellular matrix organiza-
tion (Fig 5B, S3 Table).
Hbs1L-deficient fibroblasts had increased translation efficiency of
ribosomal RNA
Patient-derived fibroblasts were grown to near confluence and then treated with cyclohexi-
mide to pause translation. mRNA not being actively translated was degraded, and then the
ribosomes were removed from the remaining mRNA. The remaining mRNA that had been
bound to ribosomes was then sequenced using next generation sequencing. The principle
component analysis and expression heatmaps demonstrated excellent reproducibility
within biological replicates and marked variance between patient fibroblasts and controls
(S3 Fig).
Ontology analysis of biological processes for the Ribo-Seq data were different than the
mRNA-Seq, however skeletal system development and morphogenesis genes remained signifi-
cantly different in both datasets (Fig 6A). Gene sets relating to embryonic development, extra-
cellular matrix and structures, and limb/appendage development were also different in the
patient Ribo-Seq samples compared to controls. Cellular component analysis for the Ribo-Seq
data showed the greatest effects in regulation of multicellular processes, anatomical structure
morphogenesis, and extracellular matrix organization (Fig 6B).
Ribosomal footprint analysis, looking at the position of the ribosomes on the mRNA tran-
scripts, showed no differences between patient and control fibroblasts (Fig 7A). We directly
assessed the coverage of 15 individual genes and found no differences in coverage individually.
Assessment of biological process mapping for the TE showed 1194 of 3323 genes with TE upre-
gulated, 51 gene sets significant at FDR<25% and 50 sets significantly enriched at p<0.01 (S3
Table). Downregulation was significant at FDR<25% for 142 gene sets and at p<0.01 for 109
gene sets. Cellular component analyses showed 236 of 461 gene sets upregulated, with 55
enriched at FDR <25% and another 55 enriched for downregulation with FDR <25% (S4
Table). Gene set enrichment analysis demonstrated marked enhancement of the TE of cyto-
solic ribosomal RNA in Hbs1L-deficient samples compared with controls (Fig 7B and 7C).
The translation of ribosomal RNA and verified 5’TOP genes were upregulated in patient sam-
ples compared to controls, in direct contrast to the effects of mTOR inhibitors on this gene set
(Fig 7D). Furthermore, assessment of mTOR, phosphorylated mTOR, 4-EBP1, and phosphor-
ylated 4-EBP1 demonstrated increased expression in patient fibroblasts (Fig 7E and 7F).
mRNA expression of mTOR in the mRNA-Seq data set was not different between patient and
control fibroblasts.
Hbs1L-deficient mice exhibit a similar phenotype to humans
The Hbs1l-KO mice were generated and extensively phenotyped by the Wellcome Sanger
Institute (S4 Fig). Both male and female KO mice weighed significantly less than controls at
various ages (Fig 8A). The mice also demonstrated abnormal facial structure that was more
prevalent in females; 86% of females had depressed nasal bones compared to 43% of males,
while another 86% of females had shortened nasal bones compared to only 14% of males (Fig
8B). Other anomalies included malocclusion, depressed zygomatic bones, dental asymmetry,
and vertebral defects such as transitional vertebrae and abnormal shape. The ophthalmologic
examination revealed atypical retinal pigmentation in the KO mice (Fig 8C and 8D). Addition-
ally, males were found to be uniformly infertile (S5 Table).
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HBS1L-deficient mice display tissue-dependent Pelota depletion
Hbs1l-KO mice were assessed for expression of Hbs1L and Pelota in a variety of tissues by
Western blot (Fig 9A). Hbs1L levels were drastically reduced in the Hbs1l-KO mice relative to
controls, though residual expression at the expected band size for Hbs1L-V3 was observed in
Fig 6. Differential pathway expression by RiboSeq. (A) Differences in expression of gene ontology pathways by
biological process. Skeletal pathways were overrepresented while eye and renal less so than the RNASeq results, all are
indicated with cartoons. (B) RiboSeq gene ontology map by biological process outputs from REVIGO ontology
software.
https://doi.org/10.1371/journal.pgen.1007917.g006
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Fig 7. RiboSeq data analysis demonstrates no difference in ribosomal footprint but enhanced translation
efficiency of ribosomal RNAs. (A) Ribosome footprinting shows similar location of ribosomes on the mRNA
transcripts in patients compared to controls. (B) Gene set enrichment analysis of cytosolic ribosome translation
efficiency (red line) and mRNA (gene line) in patients compared to controls. (C) Volcano plot demonstrate translation
efficiency (TE) of all genes with overlay of mitochondrial ribosome TE (red) and cytosolic ribosome TE (green). (D)
Comparison of translation efficiency in patients looking at all transcripts (purple) compared with known ribosomal
protein transcripts and verified 5’TOP transcripts (green). For comparison sake, the TE for the RP + 5’TOP group
from the 2012 Thoreen et al. paper using an mTOR inhibitor is also indicated (orange). (E) Western blot showing
mTOR, phospho-mTOR, 4-EBP1, and phospho-4EBP1 expression in patient vs control fibroblasts. (F) Quantification
of Western blot results in (shown in E.) normalized to GAPDH expression.
https://doi.org/10.1371/journal.pgen.1007917.g007
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various tissues. Some residual expression of V1/V2 was also noted on the Western blot, and
this is due to an incomplete knock-down with some residual protein expression, making these
mice Hbs1L reduced rather than completely null. Indeed, Hbs1L-deficient E9.5 stage embryos
displayed 10% residual expression of Hbs1l mRNA by RT-PCR (Fig 9B). Pelota expression in
the Hbs1l-KO tissues was markedly reduced in skeletal muscle, nervous system, and lung tissue
Fig 8. Hbs1L-deficient mice demonstrate growth restriction and facial dysmorphism. (A) Growth curves for
female (left panel) and male (right panel) Hbs1L-deficient mice compared with controls and historical baseline. (B)
Photographs depicting differences in snout length (first panel) and snout symmetry (second panel) in Hbs1L-deficient
versus control mice. Also examples of radiographs comparing anomalies in Hbs1L-deficient mice including shortened
nasal bone (green arrow) and zygomatic bone depression (yellow arrow). (C) Representative photos of retinas of wild
type and Hbs1L-deficient mice. (D) Distribution plot demonstrating the prevalence of retinal anomalies in Hbs1L-
deficient versus control mice.
https://doi.org/10.1371/journal.pgen.1007917.g008
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compared to WT (Fig 9A). Interestingly, Pelota expression was abundant in the KO liver and
spleen, though still reduced from controls. When we treated mouse control and Hbs1L knock-
out fibroblasts with a proteasome inhibitor, Pelota protein was increased when the mouse
Hbs1L-deficient fibroblasts were treated with the proteasome inhibitor at non-toxic doses (Fig
9C and 9D).
Discussion
In lower eukaryotes, Hbs1 protein has been established as a critical factor in several transla-
tional processes for its ability to bind with Pelota and perform ribosomal recycling. Pelota is a
known interacting partner of Hbs1L, and we noted a marked reduction in Pelota protein levels
in patient cell lines despite normal PELO transcript levels. This effect was also observed in the
majority of murine tissues. One explanation for this finding is that Pelota stability is disrupted
in the absence of Hbs1L, and destabilization of its tertiary structure leads to premature degra-
dation of the protein in vivo. In concordance with this hypothesis, treating both patient fibro-
blasts and Hbs1L-deficient mouse fibroblasts with a specific dose of proteasome inhibitor
Fig 9. Expression of Hbs1L and Pelota in Hbs1L-deficient mice. (A) Western blot portraying Hbs1L and Pelota protein expression in mouse tissues as
indicated. Liver and lung lanes for Hbs1L were spliced due to a loading error, but are otherwise unedited. (B) Relative quantification (RQ) of HBS1L
transcript expression as determined by RT-PCR in HBS1L-KO, heterozygous, and WT mice. Beta-2-microglobulin was used as the housekeeping gene
for relative quantification calculations, and mice were analyzed at E9.5. (C) Western blot of Pelota and GAPDH expression in control and Hbs1LKO
fibroblasts treated with indicated doses of the proteasome inhibitor bortezomib. (D) Quantification of Pelota band signal in (C) relative to GAPDH
expression.
https://doi.org/10.1371/journal.pgen.1007917.g009
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induced an increase in Pelota levels. This effect was also observed in control cells, indicating
that the proteolytic degradation pathway is responsible for regulating Pelota levels under nor-
mal conditions. Similar observations of coordinate regulation at the post-translational level
have been described for paralogous translation factors eRF1 and eRF3 [28, 29], affirming a pat-
tern in which trGTPases and their binding partners are targeted for degradation when they are
in an unbound state.
Monosomes are traditionally considered inactive complexes, consisting of “vacant couples”
of large and small subunits which stably associate in the cytoplasm in the absence of mRNA
[30]. When synthetic demand increases, monosomal subunits typically dissociate from one
another and then re-associate in the presence of an mRNA transcript to initiate translation.
The mechanism by which the subunits are split has not been well-characterized, and, although
Pelota:Hbs1L has been shown to engage in ribosomal splitting in other contexts including
ribosomal rescue [15, 16, 31] and translational re-initiation after cell stress [17]; our findings
suggest that it may also be involved in pre-translational dissociation of cytosolic monosome
complexes. Human Hbs1L-deficient fibroblasts displayed increased levels of 80S monosomes
relative to controls, suggesting that Hbs1L deficiency may impair translation initiation by pre-
venting the dissociation of monosomes into translationally available subunits. This has been
previously shown for yeast Hbs1, where a mutant Dom34 caused increased accumulation of
inactive 80S ribosomes both at baseline and following starvation [32]. The heightened baseline
monosome peak in patient cells may represent a missing link to the initial rate-limiting step of
translation initiation.
Alternatively, the enhanced monosome peak could reflect a population of monosomes that
are unable to dissociate due to incomplete salvation from a previous round of aberrant transla-
tion or a defect in the ribosome itself. In yeast, aggregated monosomes induced by Dom34
deficiency are resistant to dissociation at low Mg2+ concentrations, indicating that they are not
affected by the electrophysiological conditions that regulate the natural equilibrium between
free and paired ribosomal subunits [33]. We profiled several pre-rRNA species in our patient’s
cells to address the possibility of a defective rRNA processing pathway leading to a population
of “stuck” monosomes; however, no significant deficits in ribosomal processing were observed.
It is likely that Pelota:Hbs1L regulates monosome binding at the post-translational level, either
through direct contact with the inactive complex or through critical events that occur during
ribosomal rescue from aberrant translation.
Analysis of mRNA-Seq data demonstrated strong correlation with the patient’s clinical phe-
notype. Skeletal, renal/urogenital, and eye development biological process pathways were all
significantly different in patient versus control fibroblasts, corresponding to the clinical phe-
notype of skeletal, urogenital and ocular anomalies. There was also a significant difference in
axon development genes, and this suggests a neuronal etiology of the patient’s diffuse
weakness.
Ribo-Seq is a technique that sequences only the RNA being actively transcribed by the ribo-
some [34–37]. We used Ribo-Seq to assess whether there was clustering of ribosomes at a par-
ticular region of the mRNA sequences. For instance, if there is a defect in non-stop decay
increased ribosome coverage at the 5’ end of the transcript would be expected. Ribosomal foot-
print analysis showed no difference in the ribosomal footprint in patient versus control fibro-
blasts. Hbs1 has been shown in yeast and plant systems to function with Pelota in NSD [8–10].
The footprinting is an indirect assessment of NSD and supports the shRNA data showing no
differences in NSD. This difference might be due to differences in the importance of the
Hbs1LV1/V2 isoforms for NSD and NGD in the human compared with yeast. However, it
is also possible that it is a function of footprinting strategy, as others have recently shown with
an epidermal Pelota-deficient model that shorter length sequencing (20–21 nt) revealed
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differences in footprinting where standard length footprints (28–34 nt) did not [38]. This
deserves further investigation.
In addition to the position mapping of the ribosomes, Ribo-Seq was also used to assess
translation efficiency by comparing with the mRNA-Seq data. Strikingly, efficiency was dra-
matically increased for cytosolic ribosomal RNAs compared with control fibroblasts. The ribo-
somal genes upregulated correspond with the ribosomal RNAs known to be upregulated by
mTOR and phosphorylation of 4-EBP [39]. In accordance with this likely mechanism, levels of
phosphorylated and native mTOR and 4-EBP proteins were all increased in the Hbs1L defi-
cient fibroblasts compared with controls. This indicates that the enhanced ribosomal transla-
tion is likely to be an mTOR mediated response to the diminished ribosomal pool.
Hbs1l-KO mice demonstrated abundant Pelota expression in the liver and kidney despite
the absence of Hbs1L. In addition, others have shown an important role for Pelota in epider-
mal regulation [38], and the Hbs1L-deficient patient did not demonstrate any skin phenotype.
Tissue-specific binding of Pelota with novel interacting partner GTPBP2 in central nervous tis-
sue has recently been reported [40], and it is possible that another Pelota binding partner exists
in the liver, kidney, and skin, making Hbs1L less critical for the health of these tissues. Alterna-
tively, it could be that ribosomal RNA upregulation seen in the Hbs1L-deficient human fibro-
blasts is not as robust in tissues that demonstrate a phenotype, causing them to be unable to
overcome the inability to re-utilize unbound 80S monosomes.
These findings begin to detail an intricate and variegated role for Pelota:Hbs1L in mamma-
lian translational processes. This is further complicated by the isoforms of Hbs1L, and the par-
ticular functional differences between Hbs1LV1/V2 and Hbs1LV3. We have demonstrated
that Hbs1LV1/V2 deficiency leads to diminished Pelota in mammals. Additionally, we show
that deficiency of Hbs1L:Pelota complex leads to increased levels of 80S ribosomal monosomes
as well as an increase in translation of ribosomal RNA. This appears to be an mTOR-depen-
dent phenomenon. Fibroblasts from the patient exhibited altered expression of gene families
related to skeletal development, renal development, and ocular development, relating well to
the clinical phenotype of the patient. Skeletal gene pathways and many developmental path-
ways were also significantly altered in the Ribo-Seq analysis, indicating differential translation
of these gene sets compared to controls. In addition to our biological insights, we have identi-
fied proteasome inhibition to be effective in increasing the levels of Pelota in Hbs1L-deficient
patients, which may have therapeutic potential.
Methods
Ethics statement
The IRB at Boston Children’s Hospital approved the human cell work under the protocol 10-
02-0253. The IUCAC at Boston Children’s Hospital approved our mouse work (approval
number 16-06-3182R). The work followed the Guide for the Care and Use of Laboratory Ani-
mals and all of the regulatory protocols set forth by the Boston Children’s Hospital Animal
Resources at Children’s Hospital (ARCH) facility.
Generation of Hbs1l-deficient mice
Mice with a targeted pre-conditional mutation in Hbs1l containing a LacZ reporter allele
(“knockout-first” [41]) were obtained from the International Knockout Mouse Consortium
(Knockout Mouse Project (KOMP) Repository, IKMC project 79564; http://www.
mousephenotype.org/data/alleles/MGI:1891704/tm1a(KOMP)Wtsi), developed by the Well-
come Sanger Institute (Hinxton CB10 1SA, UK) [41–44]. In brief, embryonic stem (ES)
cells (line JM8A3.N1 [43]) were cultured according to the standard KOMP protocol and
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electroporated using the targeting vector HTGRS06009_A_B02 (Fig 7). The targeting vector
contained an IRES:LacZ trapping cassette and a floxed promoter-driven Neo-cassette, which
was inserted into introns 4–5 of the murine Hbs1l gene. FRT sites flanked the LacZ and Neo
cassettes and LoxP sites flanked exon 5, which was targeted for its critical ability to create
frameshift mutations in Hbs1l splice variants V1 and V2 when deleted. Splicing across the
gene-trap insertion disrupted Hbs1l gene function and rendered a null initial allele (Hbs1ltm1a).
ES cells carrying the Hbs1ltm1a allele (clone EPD0693_2_A02) were injected into C57BL/J blas-
tocysts, which were subsequently implanted into the uterine horns of C57BL/6 mice. Chimeras
and subsequent progeny were mated to 6N Taconic wild-type mice for germline production
and colony expansion. Heterozygous progeny were cross-bred to produce homozygous knock-
out-first (Hbs1l-KO) mice and wild-type (WT) controls. Mice were quarantined at Charles
River Laboratories (Worcester, MA, USA) before import into our animal facility at Boston
Children’s Hospital (Boston, MA, USA). Animal study protocols were approved and moni-
tored by the Institutional Animal Care and Use Committee (IACUC) at our institution.
Genotypes were confirmed by PCR using the Hbs1l forward primer (Hbs1l_F: 5’-TCTAAT
TCATGTGTGCCGCC-3’) and reverse primer (Hbs1l_R: 5’-TCCTGTGTTTTACCTGCATA
GAGC’3’) which flanked the targeted exon 5, producing the WT PCR product of 483 bp. Addi-
tion of the targeting cassette specific primer (Hbs1l_Cas: 5’-TCGTGGTATCGTTATGCGCC-
3’) to the PCR master mixes to induce multiplex reactions generated a mutant-specific allele of
338 bp.
Phenotyping of Hbs1L-deficient mice
Mouse phenotyping procedures were performed by the Wellcome Sanger Institute (WSI) in
accordance with the protocols described under the MGP Select Pipeline (http://www.
mousephenotype.org/impress/procedures/15). Body weight was measured twice weekly in
Hbs1l-KO and WT mice between three and sixteen weeks of age. Further phenotyping mea-
sures included hematology, eye morphology, fertility, morphology, clinical chemistry, and
body composition.
Culturing of human cell lines
Patient-derived human dermal fibroblasts (cell line 128–01) were harvested from skin biopsy
samples using standard methods. Three fibroblast control cell lines (59 or “control 1”, 2104 or
“control 2”, and 2127 or “control 3”) were obtained from our stored cell lines and our collabo-
rators. Fibroblasts were grown to roughly 80% confluency in DMEM media with 15% FBS and
penicillin-streptomycin glutamate in vertical T75 flasks. Cells were lifted by trypsin digestion
and pelleted at 1000 rpm at room temperature for 8 minutes (Allegra X-12R centrifuge with
SX4750A rotor, Beckman Coulter, Brea, CA, USA).
EBV-transformed cells (lymphoblastoid cell lines, or LCLs) were developed by co-culture of
competent EBV with patient-derived monocytes as previously described [45]. Two human
LCL control cell lines (Ncc and N2) were obtained from our collaborators. LCLs were grown
in RPMI 1640 media with 15% FBS and penicillin-streptomycin glutamate in vertical T75
flasks. Cells were grown in suspension and pelleted by centrifugation at 1300 rpm for 10 min-
utes at room temperature (Allegra X-12R centrifuge with SX4750A rotor Beckman Coulter).
RT-PCR analyses
For human mRNA extraction, patient and control fibroblasts were trypsinized and pelleted
(Allegra X-12R centrifuge with SX4750A rotor, Beckman Coulter) at 1000 RPM for eight
minutes at room temperature, and mRNA was isolated from cell pellets using the AllPrep
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DNA/RNA Mini Kit (Qiagen, Valencia, CA, USA). For mouse extraction, gastrocnemius
muscles were removed from euthanized animals, frozen in cold methylbutane and stored
at -80C for several months prior experimentation. mRNA was extracted from frozen
skeletal muscle tissue using the RNeasy fibrous tissue mini kit (Qiagen) according to the
manufacturer’s instructions. For both human and mouse samples, mRNA was reverse tran-
scribed into cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen,
Carlsbad, CA, USA) and genomic DNA was eliminated using the RNase-Free DNase set
(Qiagen).
Experimental replicates for RT-PCR contained 80 ng of human or mouse cDNA combined
with appropriate primers (described in S6 Table) and Fast SYBR Green (Invitrogen) according
to the manufacturer’s instructions. Reactions were run under standard conditions using the
ABI Step One Plus qPCR machine (Thermo Fisher Scientific, Waltham, MA, USA) and ana-
lyzed using the StepOne Real-Time PCR System (Thermo Fisher Scientific).
Tissue from E9.5 embryos was homogenized and total RNA was extracted as above. 200 ng
of extracted RNA was used in a 10 μl reaction using the TaqMan RNA-to-CT One-Step Kit
(Applied Biosystems, Foster City, CA, USA). TaqMan probe Mm03807425_g1 (Applied Bio-
systems), flanking the Hbs1l splice acceptor region between exons 4 and 5 (Ensembl Transcript
ID: ENSMUST00000219915.1), was used with primer-limited B2m endogenous control
(Applied Biosystems) in a multiplex reaction. Reactions were performed in triplicate using the
Viia 7 Real-Time PCR System (Applied Biosystems).
Western blot analyses
Human protein isolates were prepared from fibroblasts and LCLs in lysis buffer, and mouse
protein isolates were prepared from homogenized muscle and organ tissues that were boiled
at 100˚C for five minutes. Protein samples were electrophoresed through 4–12% NuPage Bis-
Tris Gel (Thermo Fisher Scientific) at 200V for 50–60 minutes and then transferred onto a
PVDF membrane overnight at 10V and 4˚C. Membranes were blocked in blocking solution
(5% blocking-grade non-fat dry milk in 1X TBS Tween-20 (TBS-T)) for one hour and then
incubated overnight at 4˚C with primary antibody diluted in blocking solution at the follow-
ing concentrations: rabbit anti-Hbs1L (10359–1 AP, Proteintech Group Inc., Chicago, IL,
USA), 1:500 for human and mouse; rabbit anti-Pelota (ab140615, Abcam, Cambridge, UK),
1:2,000 for human; rabbit anti-Pelota (10582-1-AP, Proteintech Group Inc.), 1:1,000 for mice;
and rabbit anti-ABCE1 (ab32270, Abcam), 1:1,000 for human. The following antibodies were
used at 1:500 concentration for 2 hour incubation: Phospho-4E-BP1 (Thr37/46) 236B4 (#2855
Cell Signaling,) 4E-BP1 (53H11) (#9644, Cell Signaling); Phospho-mTOR (Ser2481) (#2974,
Cell Signaling); mTOR (7C10) (#2983, Cell Signaling). Membranes were then washed three
times for ten minutes in TBS-T and incubated with HRP-conjugated goat anti-rabbit second-
ary antibody (ab6721, Abcam) at a concentration of 1:2,000 in blocking buffer at room
temperature for one hour, then subjected to three more ten-minute washes in TBS-T and
developed using SuperSignal West Pico Chemiluminescent Substrate (Fisher Scientific,
Hampton, NH, USA) for ten minutes. Developed membranes were imaged on an Image Sta-
tion 440 (Kodak DS; Eastman Kodak Co., Rochester, NY, USA). After imaging, membranes
were stripped and incubated with mouse anti-GAPDH primary antibody (ab8245, Abcam)
diluted in blocking buffer to a concentration of 1:10,000 for human (1:5000 for the phosphor-
ylation mTOR and 4-EBP assays) and 1:4,000 for mice for one hour at room temperature, and
then developed and imaged following the same procedure as previously described. Protein
expression data was analyzed using Quantity One software (v. 4.2.1; Bio-Rad Laboratories,
Hercules, CA, USA).
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Proteasome inhibition assay
Patient and control fibroblasts, and separately Hbs1L knock out and control mouse fibroblasts,
were treated with the 20S proteasome inhibitor Bortezomib at a dose of either 0 mg/mL (con-
ditional controls), 0.2 mg/mL, 0.5 mg/mL, or 1.0 mg/mL. Protein isolates were prepared from
treated cells 40 hours after Bortezomib administration and Pelota protein expression was ana-
lyzed by Western blot using the same methods described previously.
Northern blot analyses
Patient and control LCLs were pelleted at 1300 RPM (Allegra X-12R centrifuge with SX4750A
rotor, Beckman Coulter) for 10 minutes at room temperature. Total RNAs were extracted with
TRIzol reagent (Invitrogen) from cell pellets containing 10–20 x 106 cells. The aqueous phase
was further extracted with phenol-chloroform-isoamyl alcohol (25:24:1; Sigma), then with
chloroform. Total RNAs were recovered after precipitation with 2-propanol.
For Northern blot analyses, RNAs were dissolved in formamide, denatured for 10 minutes
at 70˚C and separated on a 1.1% agarose gel containing 1.2% formaldehyde and 1X Tri/Tri
buffer (30 mM triethanolamine, 30 mM tricine, pH 7.9) (3 μg of RNAs per lane). RNAs were
transferred to a Hybond N+ nylon membrane (GE Healthcare, Orsay, France) by passive trans-
fer. After UV cross-linking, pre-hybridization of the membrane was performed for 1 hour at
45˚C in 6X SSC, 5X Denhardt’s solution, 0.5% SDS, 0.9 g/ml tRNA. The 5’-radiolabeled oligo-
nucleotide probe was incubated overnight at 4˚C. The sequences of the RNA probes were: 5’-
ITS1 (5’-CCTCGCCCTCCGGGCTCCGTTAATGATC-3’), ITS2 (ITS2b: 5’-CTGCGAGGGA
ACCCCCAGCCGCGCA-3’ and ITS2d/e: 5’-GCGCGACGGCGGACGACACCGCGGCGTC-
3’), 18S (5’-TTTACTTCCTCTAGATAGTCAAGTTCGACC-3’), 28S (5’-CCCGTTCCCTTGG
CTGTGGTTTCGCTAGATA-3’). Membranes were subjected to two ten-minute washes in 2X
SSC with 0.1% SDS and one ten-minute wash in 1X SSC with 0.1% SDS and then exposed. Sig-
nals were acquired with a Typhoon Trio PhosphorImager (GE Healthcare, Boston, MA, USA)
and quantified using the MultiGauge software (Fujifilm, Tokyo, Japan).
The assay was repeated using siRNA-treated HeLa cells. Two 19-mer siRNAs (Eurogentec,
Seraing, Belgium) were used to silence expression of the HBS1L mRNAs in HeLa cells. The
first siRNA (HBS1L-1: 5’-GCAGUUCUGAAGAACAAGUdTdT-3’) targeted all three HBS1L
splice variants, whereas the second (HBS1L-2: 5’-CCAGUAGAUUCCCAGACAUdTdT-3’)
targeted V1 and V2 mRNAs only. The efficiency of both probes was verified by Western blot
analysis. Each siRNA solution was added at a final concentration of 500 nM to 200 μl of cell
suspension (50 x 106 cells/ml diluted in Na phosphate buffer, pH 7.25, containing 250 mM
sucrose and 1 mM MgCl2). Electro-transformation was performed at 240 V with a Gene Pulser
(Bio-Rad, Hercules, CA, USA). Control HeLa cells were electro-transformed with a scramble
siRNA (siRNA-negative control duplex; Eurogentec, Liège, Belgium). After a ten-minute incu-
bation at room temperature, cells were plated and grown in in DMEM Gibco media (Thermo
Fisher Scientific) supplemented with 10% fetal bovine serum and 1 mM sodium pyruvate
(Sigma-Aldrich, St. Louis, MO, USA) at 37˚C for 48 hours. Total RNA was then isolated, ana-
lyzed by Northern blot, and quantified using the same procedures as previously described.
Polysome profiling
For glucose starvation assays, media was removed from patient and control fibroblast cultures
at roughly 75% confluence and replaced with either DMEM with 15% FBS (fibroblast standard
growth media) or DMEM without FBS (fibroblast starvation media). This assay was repeated
in patient and control LCLs using RPMI with 15% FBS (LCL standard growth media) and
RPMI without FBS (LCL starvation media). Antibiotics were not added at this stage to
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diminish any potential interference with ribosomal activity. Cells were then grown to near-
confluence (roughly 80–90%), as completely confluent cells will down-regulate translation.
Cell lysates were prepared from fibroblasts after 24 hours in starved or fed conditions and
polysome profiles were assessed by previously published methods [2, 3, 15, 46].
Cells were washed once with the ice-cold buffer: 20 mM Tris-HCl, 50 mM NaCl, 50 mM
KCl, 10 mM MgCl2, 0.1 mg/ml cycloheximide while attached to the cell culture plate. Lysis was
done in the same buffer supplemented with 1% Triton X100, protease inhibitors (Roche), 1
mM DTT, and 40 U/ml Superase-In (Thermo Fisher Scientific). Cell debris was removed by
the centrifugation at 12.000 g for 4 min. Cleared lysates were loaded on 10–50 sucrose gradi-
ents and spun 3 hours at 35.000 g. For ribosome profiling, the concentration of magnesium
was lowered to 5 mM, lysates were pre-treated with 1000 U RNase T1 (Epicentre) for 30 min
at room temperature, and the monosomal peak was collected for further Ribo-seq assay. There
was no sign of ribosomal degradation and over digestion as a result of such treatment.
mRNA-Seq library preparation and sequencing
Total RNA was isolated from aliquots of the same lysates used for ribosomal profiling. Trizol
LS (Thermo Fisher Scientific) followed by the Direct-zol kit (Zymo Research) ware used for
RNA extraction. The library was prepared by the Dana Farber Next Generation Sequencing
Core Facility using a Kapa library prep kit. Sequencing was done on an Illumina NextSeq 500
using single-end 75bp reads.
Ribo-seq library preparation and sequencing
Ribosome protected footprints were isolated from sucrose gradient fractions with Trizol LS
(Thermo Fisher Scientific) and Direct-Zol kit (Zymo Research). Libraries were prepared as
described previously [47]. Briefly, ribosomal footprints (25–32 nt) were cut and eluted from
the polyacrylamide gel, the preadenylated adapter was ligated to footprints and reverse tran-
scription performed with individually barcoded primers. After PCR amplification, libraries
were pooled together and sequenced on Illumina high-throughput sequencer.
Sequencing data analysis
An analytical pipeline including calling differentially expressed genes, gene set enrichment
analysis, estimating translation efficiencies, et cetera is available here: https://github.com/
germaximus/OConnell_2018. Raw sequencing files are accessible from NCBI Gene Expression
Omnibus database: GSE123564
Gene ontology analyses
For ontology analyses, ranked gene sets were uploaded to GOrilla gene ontology assignment
software (http://cbl-gorilla.cs.technion.ac.il) and output parameter was selected as process or
component depending on the gene list uploaded (biological process versus cellular compo-
nent) [48, 49]. Outputs from GOrilla were then uploaded to REViGO (http://revigo.irb.hr)
and the default medium allowed similarity was used [50].
Statistical approach
Data are reported as mean ± standard error of the mean (SEM) unless indicated otherwise. Pro-
tein expression data derived from Western blots were normalized to the loading control and
then calculated as fold change relative to the expression level of the experimental control(s).
Relative quantification of gene expression data derived from RT-PCR experiments was
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performed using the 2-ΔΔCT method. rRNA and pre-rRNA expression data derived from North-
ern blots were calculated as log2 ratios of product to precursor pre-rRNA species and 18S to
28S rRNAs relative to three control cell lines. The single-source nature of our biological sample
representing human Hbs1L-deficiency precluded the use of tests of statistical significance in
some of our human experimental analyses, though several control samples and a minimum of
three technical replicates for each sample were used for all human cell line experiments to
increase the power. When replicates were sufficient, as for polysome profiling of fibroblast cul-
tures, we used paired t test to compare patient to control replicates. Statistical analyses for RNA
Seq and RiboSeq analyses were calculated using the Github GSEA package in R. Gene ontology
significance in GOrilla was assessed using the minimum-hypergeometric (mHG) statistic in R
and p values were assigned to be>10^-3. For mouse phenotyping, morphological and X-ray
data were analyzed using the Fisher Exact Test framework, and body compositional, hemato-
logical, and clinical chemistry data were analyzed using the Mixed Model framework (linear
mixed-effects model, equation with or without weight). Fertility results were supplied as data.
Supporting information
S1 Fig. Ribosomal RNA and polysome profiles are similar in siRNA Hbs1L-knockdown
and control HeLa cells. (A) Northern blot analysis of total RNAs extracted from HeLa cells
treated with siRNA HBS1L-1 (HBS1L-V1, V2, and V3 knockdown), HBS1L-V2 (HBS1L-V1
and V2 knockdown only), or controls (scramble siRNA). Pre-rRNA species were evidenced
with 5’ITS1 and ITS2 probes, revealing precursors to the 18S rRNA (component of the small
ribosomal subunit) and the 5.8S and 28S rRNAs (components of the large ribosomal subunit),
respectively. (B) Pre-rRNAs were quantified and log2 ratios of product to precursor pre-rRNA
species, or 18S to 28S rRNAs, were calculated for cells treated with HBS1L-1 and HBS1L-2 siR-
NAs. The data were obtained from 3 independent experiments (± S.E.M.). (C) Western blot
analysis of total protein extracts from cells treated with scramble, HBS1L-1, or HBS1L-2 siR-
NAs shown in A. Hbs1L levels were assessed relative to an α-actin loading control.
(TIFF)
S2 Fig. Quality control analysis of RNASeq. A.) PCA showing clustering of patient replicates
(red, 5 replicates from 2 separate experiments) and controls (green and blue, 2 replicates per
control). B.) Alignment heat map demonstrating similarity of transcripts between patients and
controls.
(TIFF)
S3 Fig. Quality control analysis of RiboSeq. A.) PCA showing clustering of patient replicates
(red and green, 3 replicates each from 2 separate experiments) and controls (purple and blue,
3 replicates per control). B.) Alignment heat map demonstrating similarity of transcripts
between patients and controls.
(TIFF)
S4 Fig. Targeting vector design for Hbs1l-KO mouse model. Targeting vector
HTGRS06009_A_B02 was used for the electroporation of ES stem cells in the generation of
Hbs1l-KO mice. The vector contained an IRES:LacZ trapping cassette and a floxed pro-
moter-driven Neo-cassette, which was inserted into introns 4–5 of the murine Hbs1l gene.
FRT sites flanked the LacZ and Neo cassettes and LoxP sites flanked critical exon 5. Splicing
across the gene-trap insertion yielded a null allele. Image retrieved from: https://www.komp.
org/ProductSheet.php?cloneID=701187.
(TIFF)
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S1 Table. Gene set enrichment analysis for mRNA expression by RNASeq for biological
process.
(CSV)
S2 Table. Gene set enrichment analysis for mRNA expression by RNASeq for cellular com-
ponent.
(CSV)
S3 Table. Gene set enrichment analysis for mRNA expression by translation efficiency for
biological process.
(CSV)
S4 Table. Gene set enrichment analysis for mRNA expression by translation efficiency for
cellular component.
(CSV)
S5 Table. Mating chart demonstrating infertility of male Hbs1l-KO mice.
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S6 Table. Primers used for human and mouse RT-PCR analyses.
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